Compare Enveric Biosciences Inc (ENVB) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.85 (market cap $2.06B). The key difference: Direxion Daily 20 Year Treasury Bull 3X Shares is far larger — about 307.9× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 10,528,006). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| ENVB | TMF | |
|---|---|---|
Market Cap | $6.69M | $2.06B |
Volume | 41,141 | 10,528,006 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $44.14 |
52-Week Low | $1.27 | $25.19 |
Typical Hold Time | 14 Days | 28 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.23, down 0.51% with elevated trading volume of 5.2 million shares. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oversold RSI readings suggest potential for near-term bounce. The ETF saw increased investor interest amid bond market volatility.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risk. Current oversold conditions may present tactical opportunities, though the bearish technical structure and interest rate sensitivity require careful risk management for investors seeking directional bond exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
